A potential AstraZeneca–Bristol Myers Squibb tie-up would not simply reshape the global drug industry. It would test whether Europe can still create companies powerful enough to compete in an age of scientific scale, geopolitical competition and rising healthcare costs.
The future of European pharmaceuticals may soon be decided not in a laboratory, but in the boardroom.
Reports that Britain’s AstraZeneca and U.S.-based Bristol Myers Squibb have held early discussions over a possible combination worth around $400 billion have immediately placed one question at the centre of Europe’s economic debate: can the continent once again build global industrial champions capable of competing at the highest level?
The talks remain preliminary and no agreement has been reached. Yet the significance of the discussions goes beyond whether a merger eventually happens. The possibility itself reflects a major transformation underway in the pharmaceutical industry: the era of blockbuster science increasingly belongs to companies with enormous financial resources, global research networks and the ability to absorb the rising cost of drug development.
For Europe, a region that has long possessed world-class universities, research institutions and healthcare systems but has struggled to produce technology giants comparable to those in the United States, the pharmaceutical sector remains one of its few remaining global strengths.
The question is whether that strength can survive the next decade.
Europe’s pharmaceutical success story was built differently
Unlike the digital economy, where American companies dominate global platforms, European pharmaceutical companies have maintained significant influence through research, specialised medicine and long-term scientific expertise.
AstraZeneca has become one of the most successful examples.
Under CEO Pascal Soriot, the company transformed itself from a traditional pharmaceutical group into a major force in oncology, rare diseases and advanced therapies. Its growth has been driven by cancer treatments and innovative medicines rather than simply relying on older blockbuster drugs.
This trajectory matters because the pharmaceutical industry is entering a more demanding era.
Developing a modern medicine can require billions of euros, years of clinical research and increasingly complex technologies, including artificial intelligence, genomics and precision medicine. Scale is becoming not only a financial advantage but a scientific one.
That reality has pushed global pharmaceutical companies toward consolidation.
The AstraZeneca–Bristol Myers discussions are part of a broader pattern that has seen major drugmakers pursue acquisitions to strengthen their pipelines, expand therapeutic areas and prepare for future patent expirations. Bristol Myers Squibb, for example, has faced pressure from the coming loss of exclusivity for major products while attempting to expand its next generation of medicines.
A European champion — or another sign of European vulnerability?
At first glance, a stronger AstraZeneca appears to represent exactly what European policymakers have been calling for: globally competitive companies capable of challenging American and Asian rivals.
But the reality is more complicated.
The pharmaceutical industry is increasingly global. Capital comes from international investors, research teams operate across continents, and major markets are no longer limited by national borders.
A deal involving a British company and an American pharmaceutical group would raise questions about where the centre of gravity of the combined company would ultimately sit.
For Britain, which has sought to maintain its position as a life-sciences powerhouse after Brexit, the issue is particularly sensitive. A company of this size would carry symbolic importance for the country’s scientific and economic ambitions. Reports have already highlighted concerns over potential political reactions if AstraZeneca’s identity or strategic base were to shift closer to the United States.
The challenge reveals a broader European dilemma.
Europe wants global companies. But global companies are not always controlled by European institutions, investors or governments.
The scale argument: why bigger may become necessary
Supporters of large pharmaceutical mergers argue that the industry’s future depends on scale.
Cancer research, immunology, gene therapies and personalised medicine require enormous investment. Larger companies can spread risk across more projects, maintain wider international trials and compete for scientific talent.
The combination of AstraZeneca’s strength in oncology and Bristol Myers Squibb’s established portfolio in cancer and cardiovascular medicine would create one of the world’s largest pharmaceutical groups if completed. Analysts have noted that the combined company could become one of the largest players globally, while also gaining a stronger position in the U.S. market.
But size alone does not guarantee success.
The pharmaceutical industry has a long history of mega-mergers producing mixed results. Large organisations can create efficiency, but they can also complicate decision-making, slow research cultures and lead to difficult integration processes.
The central question is not simply whether two companies can become one.
It is whether scientific innovation can become stronger after consolidation.
Europe’s real challenge: keeping innovation at home
The debate around AstraZeneca and Bristol Myers Squibb reflects a larger European concern: industrial competitiveness.
From semiconductors to artificial intelligence, European policymakers have repeatedly argued that strategic sectors require stronger domestic capabilities. Pharmaceuticals represent one of the rare areas where Europe still has significant global influence.
Yet maintaining that position requires more than protecting existing champions.
Europe faces several structural challenges:
- slower capital markets compared with the United States;
- fragmented investment ecosystems across countries;
- competition for scientific talent;
- increasing pressure from healthcare cost controls.
A pharmaceutical company may be invented in Europe, researched in European laboratories and still depend heavily on global capital markets to expand.
The question for policymakers is therefore not whether Europe should prevent globalisation.
It is whether Europe can create conditions where successful companies remain connected to European innovation ecosystems.
The next battle is not only about medicines — it is about economic sovereignty
The pharmaceutical industry has become part of a wider geopolitical competition.
During the pandemic, governments discovered the risks of relying heavily on international supply chains for critical medical products. Since then, healthcare has increasingly been viewed as a strategic sector alongside energy, technology and defence.
A stronger European pharmaceutical champion could strengthen the continent’s negotiating position in global healthcare markets.
However, Europe’s ambition cannot depend only on creating ever larger corporations.
The long-term challenge is building an environment where breakthrough companies emerge, scale rapidly and remain globally competitive.
The AstraZeneca–Bristol Myers Squibb discussions therefore represent more than a possible merger.
They represent a test of Europe’s industrial model.
Can a continent known for scientific excellence convert knowledge into global power?
Or will its most successful companies increasingly need to look elsewhere to achieve the scale required by the next generation of medicine?
The answer may determine whether Europe remains a pharmaceutical leader — or becomes simply a place where innovation begins before moving abroad.
Subscribe to EuroLuminant for independent European journalism.
